AR073074A1 - FORMULATIONS OF CANPHOSPHAMIDE, ITS PREPARATION AND PRODUCT - Google Patents

FORMULATIONS OF CANPHOSPHAMIDE, ITS PREPARATION AND PRODUCT

Info

Publication number
AR073074A1
AR073074A1 ARP090103165A ARP090103165A AR073074A1 AR 073074 A1 AR073074 A1 AR 073074A1 AR P090103165 A ARP090103165 A AR P090103165A AR P090103165 A ARP090103165 A AR P090103165A AR 073074 A1 AR073074 A1 AR 073074A1
Authority
AR
Argentina
Prior art keywords
canphosphamide
formulations
preparation
product
canfosfamide
Prior art date
Application number
ARP090103165A
Other languages
Spanish (es)
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc filed Critical Telik Inc
Publication of AR073074A1 publication Critical patent/AR073074A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1: Una formulacion de canfosfamida compuesta esencialmente por (50 +- 5) mg/ml de clorhidrato de canfosfamida en tampon de citrato de sodio acuoso (100 +- 10) mM a pH 4,6 +- 0,2.Claim 1: A formulation of canfosfamide consisting essentially of (50 + - 5) mg / ml of canfosfamide hydrochloride in aqueous sodium citrate buffer (100 + - 10) mM at pH 4.6 + - 0.2.

ARP090103165A 2008-08-28 2009-08-18 FORMULATIONS OF CANPHOSPHAMIDE, ITS PREPARATION AND PRODUCT AR073074A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9258008P 2008-08-28 2008-08-28

Publications (1)

Publication Number Publication Date
AR073074A1 true AR073074A1 (en) 2010-10-13

Family

ID=41168726

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103165A AR073074A1 (en) 2008-08-28 2009-08-18 FORMULATIONS OF CANPHOSPHAMIDE, ITS PREPARATION AND PRODUCT

Country Status (17)

Country Link
US (2) US20100056825A1 (en)
EP (1) EP2328591A1 (en)
JP (1) JP2012501331A (en)
KR (1) KR20110060898A (en)
CN (1) CN102123714A (en)
AR (1) AR073074A1 (en)
AU (1) AU2009286010A1 (en)
BR (1) BRPI0917518A2 (en)
CA (1) CA2733548A1 (en)
CL (1) CL2011000439A1 (en)
IL (1) IL211039A0 (en)
MX (1) MX2011001867A (en)
NZ (1) NZ591213A (en)
RU (1) RU2011109921A (en)
TW (1) TW201008599A (en)
WO (1) WO2010025011A1 (en)
ZA (1) ZA201101214B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056825A1 (en) 2008-08-28 2010-03-04 Telik, Inc. Formulations of canfosfamide and their preparation
US8324426B2 (en) 2008-08-28 2012-12-04 Telik, Inc. Formulations of canfosfamide and their preparation
WO2012115655A1 (en) * 2011-02-25 2012-08-30 Telik, Inc. Formulations of canfosfamide and their preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931441A (en) * 1988-11-09 1990-06-05 Luitpold Pharmaceuticals, Inc. Stabilized aqueous leucovorin calcium compositions
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
ES2202069T3 (en) * 1999-03-19 2004-04-01 Ranbaxy Laboratories, Ltd. PROCEDURE FOR THE PREPARATION OF A BIODAVAILABLE ORAL DOSAGE FORM OF AXETIL CEFUROXIMA.
EP1652533B2 (en) * 2003-08-08 2014-11-19 Ono Pharmaceutical Co., Ltd. Heart-slowing drug containing short-acting beta-blocker as the active ingredient
US8198247B2 (en) * 2004-12-21 2012-06-12 Telik, Inc. Process for and intermediates in the preparation of canfosfamide and its salts
JP5368093B2 (en) * 2005-08-31 2013-12-18 アブラクシス バイオサイエンス， エルエルシー Compositions and methods of preparation of poorly water-soluble drugs with increased stability
US20100056825A1 (en) 2008-08-28 2010-03-04 Telik, Inc. Formulations of canfosfamide and their preparation
US8324426B2 (en) * 2008-08-28 2012-12-04 Telik, Inc. Formulations of canfosfamide and their preparation

Also Published As

Publication number Publication date
TW201008599A (en) 2010-03-01
JP2012501331A (en) 2012-01-19
KR20110060898A (en) 2011-06-08
CN102123714A (en) 2011-07-13
US8481781B2 (en) 2013-07-09
NZ591213A (en) 2012-11-30
US20100056825A1 (en) 2010-03-04
CL2011000439A1 (en) 2011-07-15
ZA201101214B (en) 2013-07-31
CA2733548A1 (en) 2010-03-04
EP2328591A1 (en) 2011-06-08
AU2009286010A1 (en) 2010-03-04
WO2010025011A1 (en) 2010-03-04
IL211039A0 (en) 2011-04-28
US20110224175A1 (en) 2011-09-15
BRPI0917518A2 (en) 2015-11-17
RU2011109921A (en) 2012-10-10
MX2011001867A (en) 2011-04-07
WO2010025011A8 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
WO2009048148A1 (en) Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine
TNSN08061A1 (en) Liquid formulations
UA90518C2 (en) Pharmaceutical composition in the form of a tablet suitable for dissolution in the buccal cavity, comprising a narcotic active ingredient and amine
NO20043998L (en) Oral administration for heavily soluble basic active ingredients
CU23367A3 (en) FORMULATION OF MOXIFLOXACINO WITH COMMON SALT
ECSP10010514A (en) IMPROVED FORMULATIONS FOR ACTIVE PHARMACEUTICAL INGREDIENTS OF DEFICIENT PERMEABILITY
ECSP077387A (en) COMPOSITIONS CONTAINING PIPERACILIN, TAZOBACTAM AND AN AMINOCARBOXYL ACID IN A SODIUM LACTATE DILUENT
CY1110906T1 (en) PHARMACEUTICAL COMPOSITION FOR NON-ADMINISTRATION OF FENTANYL
UA90893C2 (en) Oral dosage forms of gemcitabine derivatives
ECSP10010052A (en) GALENIC FORMULATIONS OF ALISQUIRENO AND VALSARTAN
BR112012004967A2 (en) oral dosage form comprising at least one biologically active agent, formulation aids and magnetizable particles
AR063538A1 (en) TREATMENT OF PARKINSON'S DISEASE
MX2010005198A (en) Pharmaceutical compositions.
ATE505203T1 (en) PHARMACEUTICAL COMBINATION OF ALISKIREN AND VALSARTAN
MX2007010930A (en) Formulation for aviptadil.
AR073074A1 (en) FORMULATIONS OF CANPHOSPHAMIDE, ITS PREPARATION AND PRODUCT
WO2008128191A3 (en) Oral cephalotaxine dosage forms
EP1968606A4 (en) Preparation of pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
MEP20408A (en) Pharmaceutical dronedarone composition for parenteral administration
UY27341A1 (en) PHARMACEUTICAL FORMULATION OF MASKED FLAVOR AND PROCEDURE FOR PREPARATION.
EA201270745A1 (en) IMPROVED STABLE AQUEOUS COMPOSITION (E) -4-CARBOXYSTYRYL-4-HLORBENZYLESULPHONE
AR061155A1 (en) LIOFILIZED PREPARATIONS OF SODIUM PANTOPRAZOL FOR INJECTION
WO2007016350A3 (en) Modified release tablet formulations with enhanced mechanical properties
CL2008002025A1 (en) Oral pharmaceutical solution comprising telbivudine, sodium saccharin, a soluble flavor, benzoic acid and a citrate buffer, useful for the treatment of hepatitis B in the pediatric population, in people with swallowing difficulties and in renally impaired subjects.
WO2006087358A3 (en) Composition for adjusting water quality for administration of water sanitizer sensitive medicaments or vaccines

Legal Events

Date Code Title Description
FA Abandonment or withdrawal